Five years after Harvard researchers first received institutional permission to attempt to produce stem cell lines via somatic cell nuclear transfer (SCNT), a young scientist who worked in the Harvard program as a postdoctoral fellow has succeeded in using the process — known as therapeutic cloning — to produce a stem cell line containing the genes of a patient with type 1 diabetes.
In papers in Nature, Nature Communications, and Cell Stem Cell, that scientist, who is now at the independent New York Stem Cell Foundation (NYSCF) laboratory, and Harvard researchers, report on the SCNT advance. In addition, they report on an experiment explaining why other attempts at
Piero Anversa, Italian scientist and director of regenerative medicine at the Brigham and Women’s Hospital of Harvard University in Boston is ready to perform the first biological by-pass in history. This evening in Milan during a meeting called ‘Futuro della Sanita’ (The Future of Health), Anversa explained that he has identified human coronary stem cells able to develop into coronary artery tissue.
He said, “My dream is for someone to have a heart attack, come to the hospital, and return home healthy.” For that to occur, it will be necessary to reproduce muscle and the large coronary vessels.
Douglas A. Melton
Scientists have created stem cells from patients suffering from 10 incurable diseases, from Down syndrome to diabetes and Parkinson’s – immortal cells that might one day be turned into repair material for wasting muscles or damaged brains.
The Harvard University-led team has taken skin and bone marrow cells from diseased patients and re-programmed those cells to behave like cells from days-old embryos.
The feat allows scientists for the first time to watch muscular dystrophy and other diseases unfold in a petri dish, “that is, to watch what goes right or wrong,” said Doug Melton, co-director of the Harvard
SANUWAVE Health Inc. received a patent issued by the U.S. Patent and Trademark Office entitled “Use of Pressure Waves for Stimulation, Proliferation, Differentiation and Post-Implantation Viability of Stem Cells.”
The claims of the patent relate to the use of shock waves for stimulation of proliferation inside the body of donor stem cells. The proliferated donor stem cells are then harvested for further laboratory proliferation to create either autologous or allogeneic transplant cells.
In another step, shock waves are used to pre-treat the targeted location for tissue regeneration, to stimulate blood vessel formation and thus increase survival rate for transplanted stem cells.
In a breakthrough, Harvard scientists have discovered that stem cells loaded with the herpes virus can be used to specifically target and kill brain tumours.
Harvard Stem Cell Institute (HSCI) scientists at Massachusetts General Hospital have a potential solution for how to more effectively kill tumour cells using cancer-killing viruses.
The work, led by Khalid Shah, an HSCI Principal Faculty member, found that trapping virus-loaded stem cells in a gel and applying them to tumours significantly improved survival in mice with glioblastoma multiforme, the most common brain tumour in human adults and also the most difficult to treat (…)
Shah and his